Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.000833680700291696 -0.0504376823676532 -0.023759899958316 -0.0245935806586078
Stock impact report

InMed Pharmaceuticals GAAP EPS of -$1.01, revenue of $4.6M [Seeking Alpha]

InMed Pharmaceuticals Inc. - Common Shares (INM) 
Company Research Source: Seeking Alpha
As of June 30, 2024, we had cash, cash equivalents and short-term investments of $6.6 million. The company expects its cash will be sufficient to fund its planned operating expenses and capital expend to the end of the fourth quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues as well as the level and timing of the Company's operating expenses. More on InMed Pharmaceuticals Financial information for InMed Pharmaceuticals Recommended For You More Trending News Show less Read more
Impact Snapshot
Event Time:
INM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for INM alerts
Opt-in for
INM alerts

from News Quantified
Opt-in for
INM alerts

from News Quantified